…
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Entera Bio Ltd is a clinical-stage biotechnology company developing oral formulations of peptide and protein therapeutics using a proprietary delivery platform. Long-term growth may be driven by positive clinical data, regulatory approvals, and partnerships if oral alternatives gain adoption versus injectables.
Key risks include clinical or regulatory failure, need for continued financing, manufacturing and intellectual property challenges, and strong competition that could hinder commercialization.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -11.44M | -9.53M | -8.86M | -12.93M | -12.25M |
| Net income | -11.44M | -9.54M | -8.89M | -13.07M | -12.19M |
| Selling general administrative | 5.53M | 5.09M | 4.43M | 7.25M | 5.69M |
| Gross profit | -0.03M | 0.01M | -0.06M | 0.03M | 0.20M |
| Reconciled depreciation | 0.03M | 0.05M | 0.06M | 0.06M | 0.05M |
| Ebit | -11.44M | -9.53M | -8.86M | -13.08M | -12.22M |
| Ebitda | -11.41M | -9.48M | -8.80M | -13.02M | -12.16M |
| Depreciation and amortization | 0.03M | 0.05M | 0.06M | 0.06M | 0.05M |
| Operating income | -11.53M | -9.59M | -8.94M | -13.02M | -12.22M |
| Other operating expenses | 11.57M | 9.77M | 8.94M | 13.15M | 12.79M |
| Interest expense | - | - | - | 26.00M | 0.03M |
| Tax provision | 0.00M | 0.01M | -0.02M | 0.14M | -0.06M |
| Net interest income | 0.09M | 0.06M | 0.05M | 0.08M | -0.03M |
| Income tax expense | 11.53M | 0.01M | 0.03M | 0.14M | -0.06M |
| Total revenue | 0.04M | 0.18M | 0.01M | 0.13M | 0.57M |
| Total operating expenses | 11.53M | 9.59M | 8.88M | 13.05M | 12.41M |
| Cost of revenue | 0.04M | 0.17M | 0.06M | 0.10M | 0.37M |
| Total other income expense net | 0.09M | 0.06M | 0.08M | 0.08M | -0.03M |
| Net income from continuing ops | -11.44M | -9.54M | -9.93M | -13.07M | -12.19M |
| Net income applicable to common shares | - | - | - | -13.07M | -12.19M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 15.99M | 9.39M | 11.77M | 13.13M | 25.99M |
| Other current assets | -0.22M | 0.19M | 0.24M | 0.29M | 0.25M |
| Total liab | 2.89M | 1.31M | 1.38M | 1.37M | 3.42M |
| Total stockholder equity | 13.10M | 8.08M | 10.39M | 11.75M | 22.57M |
| Other current liab | 1.52M | 0.87M | 0.87M | -0.13M | 2.80M |
| Common stock | 0.00M | 0.00M | 0.00M | - | - |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -125.37M | -113.93M | -104.39M | -95.50M | -82.43M |
| Other liab | - | - | - | 0.03M | 0.14M |
| Other assets | 8.75M | - | - | 0.05M | 0.26M |
| Cash | 7.11M | 8.66M | 11.02M | 12.31M | 24.89M |
| Total current liabilities | 2.20M | 1.18M | 1.09M | 1.34M | 3.16M |
| Current deferred revenue | - | - | - | 0.04M | 0.01M |
| Net debt | -6.62M | -8.39M | -10.63M | -12.22M | -24.59M |
| Short term debt | 0.23M | 0.17M | 0.13M | 0.09M | 0.18M |
| Short long term debt total | 0.49M | 0.27M | 0.39M | 0.09M | 0.30M |
| Other stockholder equity | 138.43M | 121.97M | 114.73M | 107.21M | 104.95M |
| Property plant equipment | - | - | - | 0.23M | 0.40M |
| Total current assets | 7.11M | 8.97M | 11.26M | 12.85M | 25.33M |
| Net tangible assets | - | - | - | 11.75M | 22.57M |
| Net receivables | 0.22M | 0.13M | 0.00M | 0.54M | 0.18M |
| Inventory | - | - | - | -0.29M | - |
| Accounts payable | 0.45M | 0.13M | 0.08M | 1.34M | 0.17M |
| Accumulated other comprehensive income | 0.04M | 0.04M | 0.04M | 0.04M | 0.04M |
| Non currrent assets other | -0.09M | 0.01M | 0.01M | 0.10M | 0.05M |
| Non current assets total | 0.13M | 0.42M | 0.51M | 0.28M | 0.66M |
| Capital lease obligations | 0.49M | 0.27M | 0.39M | 0.09M | 0.30M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.00M | -0.01M | -0.10M | -0.02M |
| Change to liabilities | - | - | - | -0.16M | -0.14M |
| Total cashflows from investing activities | -0.11M | -0.00M | -0.02M | -0.10M | -0.02M |
| Total cash from financing activities | 13.71M | 4.48M | 6.04M | 0.01M | 25.38M |
| Change to operating activities | - | - | - | -1.61M | 1.48M |
| Net income | -11.44M | -9.54M | -8.89M | -13.07M | -12.19M |
| Change in cash | 6.23M | -2.35M | -1.29M | -12.59M | 16.30M |
| Begin period cash flow | 8.74M | 11.09M | 12.38M | 24.96M | 8.66M |
| End period cash flow | 14.97M | 8.74M | 11.09M | 12.38M | 24.96M |
| Total cash from operating activities | -7.37M | -6.82M | -7.31M | -12.50M | -9.06M |
| Issuance of capital stock | 13.44M | 3.96M | 0.01M | 0.00M | 21.80M |
| Depreciation | 0.03M | 0.05M | 0.06M | 0.06M | 0.05M |
| Other cashflows from investing activities | - | - | - | -0.06M | -0.06M |
| Change to inventory | - | - | - | - | -0.07M |
| Change to account receivables | 0.13M | -0.13M | 0.25M | -0.06M | 0.07M |
| Other cashflows from financing activities | 13.71M | 0.52M | -0.58M | 0.01M | 3.58M |
| Change to netincome | - | - | - | 2.34M | 1.66M |
| Capital expenditures | 0.11M | 0.00M | 0.02M | 0.05M | 0.02M |
| Change in working capital | 1.26M | 0.11M | -0.20M | -1.83M | 1.41M |
| Stock based compensation | 2.75M | 2.56M | 1.69M | 2.25M | 1.86M |
| Other non cash items | 0.03M | -0.01M | 1.69M | -0.08M | 0.02M |
| Free cash flow | -7.48M | -6.82M | -7.33M | -12.55M | -9.08M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ENTX Entera Bio Ltd |
0.03 0.99% |
3.05 | - | - | 1547.08 | 67.20 | 1527.79 | -1.52 |
| NVO Novo Nordisk A/S |
-1.21 2.90% |
40.40 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.15 1.14% |
531.64 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.70 0.49% |
957.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
| Name | Title | Year Born |
|---|---|---|
| Ms. Miranda J. Toledano M.B.A. | CEO & Director | 1977 |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer | 1978 |
| Ms. Dana Yaacov-Garbeli CPA | CFO & Principal Financial Officer | 1983 |
| Dr. Arthur C. Santora II, M.D., Ph.D. | Chief Medical Officer | 1951 |
| Ms. Dana Yaacov-Garbeli CPA | Chief Financial Officer | 1983 |
| Dr. Gregory Burshtein Ph.D. | Chief of Research & Development | 1977 |
| Dr. Rachel B. Wagman | Chief Clinical Advisor | NA |
| Ms. Cherin Smith | Executive VP & Head of Clinical Operations | NA |
| Dr. Constantin Itin Ph.D., R.Ph. | Head of Biopharmaceutics & Bioanalytics | NA |
| Ms. Michele McDermott | MD & EVP of Medical Affairs | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.